• Pooled analysis of five efti trials shows 7.7-month median OS benefit in responders
• IMP761, LAG-3 agonist antibody, shows promising first-in-human results
• Ongoing futility analysis for TACTI-004 expected in Q3 CY26
• Well-funded with A$68.87 million in cash as of June 2026
• Cost-reduction measures initiated to extend runway into H1 CY28

Immutep Limited, a clinical-stage biotechnology company, provided an update on its activities for the quarter ended 30 June 2026. The company reported a pooled analysis of five clinical trials of eftilagimod alfa (efti) in combination with standard-of-care therapies, showing a 7.7-month median overall survival benefit in responders. IMP761, a LAG-3 agonist antibody, delivered encouraging first-in-human results. An ongoing futility analysis for the TACTI-004 Phase III trial is expected in Q3 CY26. Immutep is well-funded with A$68.87 million in cash and has initiated cost-reduction measures to extend its runway into H1 CY28.

Cash runway extending into H1 CY28

Immutep expects to provide further insights from the root cause analysis for TACTI-004 in Q3 CY26, and additional trial updates for IMP761 in H2 CY26.